We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Neurocrine Biosciences Inc | NASDAQ:NBIX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.49 | 3.99% | 143.03 | 138.77 | 144.20 | 145.22 | 136.01 | 140.18 | 1,601,920 | 23:11:08 |
From May 2019 to May 2024
SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.
The live presentation takes place on Thursday, June 15 at 9:20am PT (12:20pm ET). The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. In April of 2017, the FDA approved INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with TD. The Company markets INGREZZA in the United States. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-300471523.html
SOURCE Neurocrine Biosciences, Inc.
Copyright 2017 PR Newswire
1 Year Neurocrine Biosciences Chart |
1 Month Neurocrine Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
